The latest domestic price inquiry of Futibatinib

Fobatinib (Futibatinib) is a targeted therapy drug for specific cancers, mainly used to treat cholangiocarcinoma (CCA). It is a tyrosine kinase inhibitor that can specifically inhibit the FGFR (fibroblast growth factor receptor) pathway and block the growth signals of tumor cells. Aberrant activation of the FGFR signaling pathway plays a key role in many types of cancer, so forbatinib provides an effective treatment option for these patients, especially when traditional treatments are ineffective.

Clinical studies of forbatinib have shown that it has a significant therapeutic effect on patients with FGFR mutations or amplifications. It can effectively control cancer progression, especially in the treatment of advanced cholangiocarcinoma (CCA), and has become one of the choices for patients.

However, forbatinib has not yet been officially launched in the Chinese market and has not been included in medical insurance. Therefore, domestic patients cannot purchase the drug directly through conventional channels. At present, forbatinib is already sold in overseas markets and has been approved mainly in Japan and other countries. In Japan, the original drug specification of forbatinib is 4mg*35 tablets, and the price is about 30,000 yuan. Please note that this price may be affected by exchange rate fluctuations and will therefore vary.

In addition to the original drug, generic drugs of forbatinib are also available in some countries, such as the Laos version of forbatinib. Its specification is also 4mg*35 tablets, but the price is relatively low, about 2500 RMB. Although generic drugs are more affordable, the ingredients are basically the same as the original drugs and they also have the same therapeutic effect.

Overall, the price of forbatinib is not clear in China, and because it is not covered by medical insurance, patients may need to pay out of pocket when purchasing it. With the progress of the drug's launch and changes in related policies, it is expected that more treatment options will be provided for domestic patients in the future.

Reference materials: https://www.lytgobi.com/